The mechanisms by which CD133 + Exo treatment improves neurocognitive recovery as well as reduces NAFLD/NASH progression, and how liver dysfunction induced by T2DM stroke possibly feeds-back to amplify neurological dysfunction have not been investigated in the current study. This evidence concerns the gene PROM1 and metabolic dysfunction-associated steatotic liver disease.